Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer

被引：18
|
作者：
Sharp, Adam [1 ,2 ]
Welti, Jonathan [1 ,2 ]
Blagg, Julian [3 ]
de Bono, Johann S. [1 ,2 ]
机构：
[1] Inst Canc Res, Prostate Canc Targeted Therapy Grp, Sutton, Surrey, England
[2] Royal Marsden NHS Fdn Trust, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England
[3] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London, England
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 17期
基金：
英国医学研究理事会;
关键词：
DOMAIN;
D O I：
10.1158/1078-0432.CCR-16-1137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. (C) 2016 AACR.
引用
收藏
页码：4280 / 4282
页数：3
相关论文
共 50 条
  • [1] Androgen receptor (AR) aberrations in castration-resistant prostate cancer
    Waltering, Kati K.
    Urbanucci, Alfonso
    Visakorpi, Tapio
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 360 (1-2) : 38 - 43
  • [2] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    [J]. FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [3] Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer
    Reichert, Zachery R.
    Hussain, Maha
    [J]. CANCER JOURNAL, 2016, 22 (05): : 326 - 329
  • [4] Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
    Graham, Laura
    Schweizer, Michael T.
    [J]. MEDICAL ONCOLOGY, 2016, 33 (05)
  • [5] Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
    Scher, HI
    Buchanan, G
    Gerald, W
    Butler, LM
    Tilley, WD
    [J]. ENDOCRINE-RELATED CANCER, 2004, 11 (03) : 459 - 476
  • [6] Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
    Laura Graham
    Michael T. Schweizer
    [J]. Medical Oncology, 2016, 33
  • [7] Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy
    De Velasco, Marco A.
    Kura, Yurie
    Sakai, Kazuko
    Hatanaka, Yuji
    Davies, Barry R.
    Campbell, Hayley
    Klein, Stephanie
    Kim, Youngsoo
    MacLeod, A. Robert
    Sugimoto, Koichi
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    Uemura, Hirotsugu
    [J]. JCI INSIGHT, 2019, 4 (17)
  • [8] Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
    R Ferraldeschi
    J Welti
    J Luo
    G Attard
    J S de Bono
    [J]. Oncogene, 2015, 34 : 1745 - 1757
  • [9] Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
    Lallous, Nada
    Dalal, Kush
    Cherkasov, Artem
    Rennie, Paul S.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06) : 12496 - 12519
  • [10] Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer
    Lv, Shidong
    Song, Qiong
    Chen, Guang
    Cheng, Erdong
    Chen, Wei
    Cole, Ryan
    Wu, Zeyu
    Pascal, Laura E.
    Wang, Ke
    Wipf, Peter
    Nelson, Joel B.
    Wei, Qiang
    Huang, Wenhua
    Wang, Zhou
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (04):
12345